Teva expands Alvotech collab with 2 more biosims, increased manufacturing oversight and a $40M investment

After Teva’s Alvotech-partnered Humira biosimilar suffered its second FDA rejection, the generics giant is stepping up its role in their long-term collaboration with increased manufacturing involvement and $40 million in funding for its partner.